Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Foamix Announces Publication of Phase 3 FMX101 Acne Study in Journal of American Academy of Dermatology
GlobeNewswire
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical-stage pharmaceutical company that specializes in developing and commercializing proprietary topical therapies for dermatological conditions, announced today the peer review publication of the Phase 3 study FX2017-22 ("Study 22") in the Journal of the American Academy of Dermatology (JAAD). Study 22 was conducted by Foamix to support the New Drug Application (NDA) submission of FMX101, which is currently under review by the FDA for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older.
"We are pleased that the prestigious JAAD has chosen to highlight Study 22 in its current edition," said Dr. Iain Stuart, Chief Scientific Officer of Foamix. "The Am erican Academy of Dermatology is the largest and most influential dermatology group in the United States and JAAD is the ideal platform to share the results from this successful Phase 3 study with the broader clinical dermatology community. As FMX101 is the first topical formulation of minocycline to reach regulatory agency review for the treatment of any disease, publication of this pivotal study in JAAD is befitting of its uniqueness and a testament to the innovation happening at Foamix."
Highlights from the study:
-- The study showed high statistically significant superiority of FMX101 compared with vehic le in both primary endpoints of absolute inflammatory lesion reduction and IGA treatment success at week 12.
-- FMX101 also met all secondary endpoints, showing statistically significant improvement in absolute reductions in both inflammatory lesions (papules, pustules and nodules) and non-inflammatory lesions (open and closed comedones).
-- There was a statistically significant reduction in inflammatory lesions versus vehicle as early as week 3 of treatment, and all subsequently assessed timepoints throughout the entire treatment course of the study.
-- Statistically, participants were no more likely to experience treatment-emergent adverse events (TEAEs) from FMX101 than from vehicle treatment. The majority of TEAEs were mild to moderate.
-- More than 95% of participants using FMX101 had no or mild skin tolerability scores at the treatment application site at week 12.
"These data show that FMX101 has potential as both a safe and effective option for patients," said Dr. T. Joseph Raoof of the Encino Research Center in Enci no, CA., a clinical investigator on the study. "As a convenient, topical formulation of minocycline for acne, FMX101 has been designed to deliver the drug's bacteriostatic and anti-inflammatory effects while minimizing systemic absorption and the resulting safety concerns associated with oral minocycline. Given that acne is the most common skin condition in the United States, FMX101 has the potential to positively impact millions of people."
"Forget cannabis edibles and cannabis leaf products. The big story right now is cannabidiol, or CBD.
Hemp is now legal in the U.S. And the most lucrative opportunity resulting from this legalization is with hemp-derived CBD products. Cannabis market researcher Brightfield Group projects that the U.S. hemp CBD market will total $22 billion by 2022. A more conservative estimate comes from investment firm Piper Jaffray, which forecasts annual U.S. hemp CBD sales of close to $15 billion by 2023.
The biggest opportunities in investing, though, can come from getting in on something big early on. It's early for the U.S. CBD market. But this CBD market will almost certainly be huge."
Keith Speights, The Motley Fool
Growing Springs
http://upperstreetmarketing.com/
Upper Street Marketing to Present at the 9th Annual LD Micro Invitational
LOS ANGELES, CA / ACCESSWIRE / May 30, 2019 / Upper Street Marketing Inc. (OTC Pink:UPPR), one of the only companies in the world to control every phase of the cannabidiol (CBD) extraction cycle from seed to consumer, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5 at 11 AM PST / 2 PM EST. President / CEO Joseph Earle will be presenting and meeting with investors. Now fully legal as a non-psychoactive product of industrial hemp, CBD has been promoted as an effective treatment for everything from arthritis to insomnia. To date, the only FDA-approved uses are for two rare forms of childhood epilepsy, but current CBD supply already falls far short of projected demand. Fortune magazine and other publications have contemplated a 100X surge in CBD consumption between now and 2023, at which point UPPR and other producers will need to ramp up output from a currently minimal 50,000 kg of isolate to as much as 3.5 million kg. An estimated 7% of Americans are currently consuming CBD products, with that population conservatively expanding 30% (to 25 million adults) by 2025. UPPR welcomes the challenge and recognizes the scope of the commercial opportunity ahead, as CEO Earle's presentation will reveal. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges" stated Chris Lahiji, while waiting in the longest TSA line in history. "Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever growing community." The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals. View Upper Street Marketing Inc.'s profile here: http://www.ldmicro.com/profile/UPPR Profiles powered by LD Micro - News Compliments of Accesswire About Upper Street Marketing Inc. Now fully legal as a non-psychoactive product of industrial hemp, cannabidiol (CBD) has been promoted as an effective treatment for everything from arthritis to insomnia. To date, the only FDA-approved uses are for two rare forms of childhood epilepsy. With one of the only integrated "seed to consumer" platforms for participating in all phases of the industry from crop to value-added commercial and clinical product development, UPPR intends to be a leader in FDA cGMP (Current Good Manufacturing Practice) capabilities in the hemp and CBD marketplace. About LD Micro LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information. Contact: Phone: (844) 535-UPPR
Address: 17311 Caminito Canasto, San Diego, CA, USA, 92127
Email: investorrelations@upperstreetmarketing.com SOURCE: Upper Street Marketing
Upper Street Marketing Secures 1.5 Million Pounds of Hemp for CBD Extraction
SAN DIEGO, CA, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Upper Street Marketing Inc. (OTC Markets: symbol UPPR) and its wholly owned subsidiary Growing Springs Holding Corp. have entered into an agreement to process 1.5 million pounds of hemp biomass into cannabidiol (CBD) isolates and distillates with a value of approximately $200 million.
Fox Organic Farms will deliver the biomass from its 830-acre Saguache, Colorado cultivation to UPPR-affiliated extraction facilities in October, where it will be converted into pharmaceutical-grade CBD products in exchange for a 50% share of the revenue.
“Ryan Fox is one of the sharpest guys transforming the Colorado agricultural landscape and we are extremely happy to get this opportunity to work with him,” noted Upper Street CEO Joseph Earle. “Hemp is a delicate crop that requires expert handling to optimize CBD extraction yields without going over federal THC limits. We’re eager to see what he brings in.”
Since Fox is a noted figure within the Colorado recreational cannabis and CBD industry, recognizing revenue will be assured that the extracts are produced and delivered — especially given the fact that current CBD supply falls far short of projected demand.
Fortune magazine and other publications have contemplated a 100X surge in CBD consumption between now and 2023, at which point UPPR and other producers will need to ramp up output from a currently minimal 50,000 kg of isolate to as much as 3.5 million kg. An estimated 7% of Americans are currently consuming CBD products, with that population conservatively expanding 30% (to 25 million adults) by 2025.
Fox already has an extensive network of commercial relationships in place through sales of CBD extracts will occur. Even though we anticipate a 10-18% CBD yield, even at a low nominal 5% CBD yield (10-18% is more common), this arrangement can easily generate substantial cash flow for UPPR while its own Colorado hemp crop approaches harvest and extraction.
Recent industry pricing on CBD isolates are running above $3,000 per pound ($7,000 per kilogram) and many organic hemp farmers target yields of 15% CBD or higher.
“While we are eager to bring in our own hemp crop, processing Fox Organic Farms biomass provides us with incremental revenue and a robust proof of concept,” Joseph Earle explains.
“Successful execution will put UPPR on the national map and makes it like that we exceed our initial $75 million revenue target for the year, opening the door to more extensive cooperation with Fox Organic Farms in the future.”
Waiting on Q2 financials now.
Total shares authorized: 300,000,000 as of date: 04/02/19
Total shares outstanding: 79,951,426 as of date: 04/02/19
Number of shares in the Public Float2
: 9,762,902 as of date: 04/02/19
Total number of shareholders of record: 80 as of date: 04/02/19
Quarterly Report - UPPR QTR 1 2019 Disclosures and incorporated Financial Statements
PDF LINK
Stock charts link is denied, but you can look up to see the status.
Absolutely!
Sitting on the 200MA ready to run! News is the catalyst!
https://www.stockcharts.com/h-sc/ui?s=IVST
Thinking they may just wanted to get past the Memorial Day holiday. No need to slow the upward momentum once positive news is released.
Keeping watch Tues morning.
Nice!!
Upper Street Marketing Updates Shareholders: CBD Crop 5 Months Away, Fully Licensed Extraction Will Follow
San Diego, CA, May 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Upper Street Marketing Inc. (OTC Markets: symbol UPPR) and its wholly-owned subsidiary, Growing Springs Holding Corporation, are pleased to announce that their first hemp crop is on track to harvest by early October and extraction facilities have been secured to start producing distillates and other extracts.
UPPR’s newly leased 12,000 square foot laboratory and manufacturing facility is fully licensed for non-psychoactive cannabidiol (CBD) extraction. Through an existing relationship with FDA-licensed pharmaceutical manufacturer, Primapharma Inc., (PPI), (www.primapharma.net) the Company will comply with cGMP (Current Good Manufacturing Practices).
Coupled with the company’s coming organic hemp crop, UPPR is poised to become one of the largest producers of pharmaceutical-grade CBD at a moment when isolates and high-quality distillates sell for $6,000 to $10,000 per kilogram, depending on volume.
“Industry averages suggest that a healthy acre of hemp biomass can translate into as many as 50 kg of CBD. This initial 300-acre cultivation certainly offers UPPR the ability to achieve our 2019 revenue target of $75 million,” stated Upper Street CEO Joseph Earle.
Earle goes on to say, “Following the full legalization of industrial hemp and regulatory requirements for FDA standards for pharmaceutical-grade CBD, demand is exponentially outpacing existing supply. The faster we can harvest and get our first extracts on the market, the better.”
Accounting for a crop cost of $20,000 - $30,000 per acre, the economic implications are considerable. Fortune magazine and other publications have contemplated a 100X surge in CBD consumption between now and 2023, at which point UPPR and other producers will need to ramp up output from a currently minimal 50,000 kg of isolate to as much as 3.5 million kg.
An estimated 7% of Americans are currently consuming CBD products, with that population conservatively expanding 30% (to 25 million adults) by 2025. Given fragmentation and inefficiency in the newly legalized industry, strategic leadership is essential, motivating UPPR’s recent purchase of 20% of Canadian cannabis/hemp project developer Catch Capital Partners in order to capitalize on what can easily become a $35 billion market opportunity.
“With Catch Capital on our team UPPR is in a strong position to provide cooperative pharmaceutical-grade hemp on both sides of the border,” CEO Joseph Earle explained. “We will be a very large player, very quickly.”
Spot on with your prediction! Still looking strong here.
I wouldn't mind seeing that! I'll be more convinced once it closes over the low .70's resistance.
Wow! Where did this volume increase come from? Very nice!
Upper Street Marketing Announces Closing of Transaction in Dynamic Canadian Market
San Diego, CA, May 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- UPPR-OTC is pleased to announce the closing of its recently announced acquisition of twenty percent of Catch Capital Partners Inc. UPPR has issued five million shares to the Principals of Catch Capital Partners. Catch Capital Partners is a Canadian company actively advancing projects in the outdoor cannabis and hemp space.
Joseph Earle, CEO of UPPR, stated, "We are very pleased to complete this strategic investment. The Catch Capital Partners team is uniquely positioned to capitalize on the dramatic shortfall in supply of recreational cannabis in Canada. Further, they have an innovative plan to create cooperative pharmaceutical grade hemp production in the Canadian market. We believe last week's significant announcement regarding Canadian licensing will benefit Catch Capital, and UPPR shareholders."
Catch Capital CEO Jeff Wareham added, "Last week was a game changer for both cannabis and hemp in Canada and for Catch Capital Partners. This is a huge advantage for Catch Partners and likely will advance our plans quickly. The licensing process for these two critical high value crops has been hindered by an apparently huge volume of applications, where paperwork may be in order, but there exists little chance of raising the necessary capital to complete the projects. Health Canada has made what appears to be a wise decision, choosing to focus on real projects, not unfunded dreams. Further, we feel this will free up limited Health Canada resources to respond to the rapidly evolving global market for hemp and cannabis products. The US Farm Bill has fundamentally changed the hemp market, and Canadians need to catch up. Our new partnership with UPPR ensures we are well positioned to grow our business in this dynamic environment."
We see you tiptoeing your way back up to .70 UPPR! Now break that .70 and I'll be extremely happy!
New Cannabis Companies:
Upper Street Marketing Inc. (OTC UPPR) Growing Springs is established and entrenched in the Colorado cannabis marketplace with significant opportunities for organic expansion and synergistic mergers and acquisitions. The business is well-officiated by an experienced c-level suite of officers and highly specialized cannabis operational personnel. Until a name change is completed and approved, Growing Springs trades under the name and ticker of its recent merger partner, Upper Street Marketing (OTC:UPPR).
Oh no, this load time! We're entering rocket territory at these levels! T minus...
Upper Street Marketing Announces New Facility for CBD Extraction and Plan for CBD Products
San Diego, CA, May 10, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Upper Street Marketing Inc. (OTC Markets: symbol UPPR) and its wholly-owned subsidiary, Growing Springs Holding Corporation, are pleased to announce that we have entered into a five year lease, with five year renewals, with Cal-Sorrento Realty, San Diego, California, for a state of the art 12,000 square foot laboratory and manufacturing facility. The facility is licensed for CBD extraction.
The laboratory and manufacturing facility location is adjacent to Primapharma Inc., (PPI) a collaborative partner with UPPR (http://primapharma.net). UPPR has previously established a long-term agreement with PPI, an FDA licensed, cGMP pharmaceutical manufacturer. UPPR along with its wholly owned subsidiary, Growing Springs Holdings Corporation (GSHC) intends to manufacture and develop fully FDA cGMP standards for the production of various CBD distillates and isolates for commercial applications as well as research and clinical studies.
PPI will provide technical expertise, staffing and other resources necessary to complete facilities and the necessary documentation and processes for an FDA licensed facility devoted to CBD extracts derived from Hemp. UPPR will provide the necessary funding for dedicated staff, the equipment and facilities. “We are particularly excited about this agreement with PPI. This is a world class facility! The agreement further addresses the need for FDA manufacturing and production standards needed in the industrial hemp CBD industry,” said Joseph Earle, UPPR President and CEO.
Wholesale CBD isolate and distillate are currently selling for approximately $6,000 to over $10,000 per kilogram, depending on volume. With our proximity to Primapharma on the campus, and with Primapharma being a licensed FDA manufacturer and laboratory, UPPR can apply to extended FDA licensing to the new facility.
UPPR seeks to be a world class wholesale provider to the hyper-growth CBD markets of cosmetics, sports drinks, alcohol and non-alcohol beverages, pet foods, food infused edibles, and many other products soon to incorporate CBD extracts.
Joseph Earle, Upper Street CEO, said, “Having this facility opens up revenue opportunities in many areas for UPPR. We plan on prioritizing opportunities to focus on high volume high margin wholesale customers.”
Further to our news release of April 25, 2019, below is a corporate update.
We embarked on an ambitious plan in 2018 to become the first and likely the largest cGMP CBD producer and marketing company in the United States and a major player in the global market for what we see as the most significant new market in many years.
So what is this significant new market and what is the potential size of this market?
In a recent Fortune Magazine article, dated February 25th, 2019 they quoted a new analysis by Cowen & Co, nearly 7% of Americans are already using cannabidiol (CBD), placing the potential for the much hyped cannabis compound at $35 Billion by 2025.
They went on to say that they “conservatively” see CBD use growing to 10% of U.S. adults or 25 million consumers by 2025.
To date CBD’s are promoted as an effective treatment for everything from arthritis to insomnia. The only FDA approved remedy is for two rare forms of childhood epilepsy.
UPPR via its subsidiaries intends to be at the forefront of this change. UPPR is a vertically integrated “seed to consumer” cultivator and manufacturer FDA compliant CBD products.
UPPR intends to be an industry leader in FDA cGMP (Current Good Manufacturing Practice) capabilities in the hemp and CBD marketplace.
Many industry analysts expect additional scrutiny of the CBD industry. UPPR intends to comply with all FDA standards regulations for CBDs. “UPPR intends to lead the industry,” quotes Joseph Earle, CEO. Earle goes on to say that “Further FDA scrutiny is certainly bound to happen.”
We at Upper Street/Growing Springs are at the forefront of that trend, and back it up with our strategic partnership with Primapharma (www.primapharma.net) which we announced on January 22, 2019, to develop fully cGMP CBD oils and isolate, as well as research and clinical studies.
In order to be a “from seed to consumer” CBD company we grow our own hemp, extract the high quality CBD from our own hemp and with our partnership with Primapharma are developing cGMP products for consumers.
This is how we are unique and how we are attacking this large and rapidly growing market that is estimated to be a $16 Billion market within the next seven years.
That's a plate full of positives! Looking forward to this!
You too! Appreciate you keeping us informed here!
The kind of news I'm waiting for!
Yep! UPPR making moves now!
Upper Street Marketing to Grow 300 Acres of Hemp and Extract CBD in 2019 and up to 7,000 Acres in 2020
San Diego, CA, May 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Upper Street Marketing Inc. (OTC Markets: symbol UPPR) and its wholly-owned subsidiary, Growing Springs Holding Corporation, are pleased to announce that it has completed assembling all the resources for planting and nutrition for our hemp crop of 300 acres for crop year 2019. The acreage in question is certified organic. CBD yields through extraction may exceed $200,000 per acre at current wholesale pricing.
Upper Street Marketing Inc., through its wholly owned subsidiary Growing Springs Holdings Corporation, has an experienced cultivation team led by Roger Christensen of Center, Colorado. Mr. Christensen has over 25 years-experience in organic farming and product distribution.
Based on the 2019 crop estimates, UPPR expects harvest and CBD extraction in late September or early October. UPPR extraction with its pharmaceutical partner, PrimaPharma Inc., of San Diego, CA will target revenue in excess of $75 million in CBD extracts for 2019.
Upper Street CEO Joseph Earle stated, “Upper Street is now positioned for significant revenue growth for 2019 and we are already planning on expanding our hemp crops and CBD extraction by growing approximately 7,000 acres of hemp in 2020.”
Further to our news release of April 25, 2019, below is a corporate update.
We embarked on an ambitious plan in 2018 to become the first and likely the largest cGMP CBD producer and marketing company in the United States and a major player in the global market for what we see as the most significant new market in many years.
In a recent Fortune Magazine article, dated February 25th, 2019 they quoted a news analysis by Cowen & Co, nearly 7% of Americans are already using cannabidiol (CBD), placing the potential for the much-hyped cannabis compound at $35 Billion by 2025. They went on to say that they “conservatively” see CBD use growing to 30% CAGR of U.S. adults or 25 million consumers by 2025.
CBD is promoted as an effective treatment for everything from arthritis to insomnia. To date, the only FDA approved uses are for two rare forms of childhood epilepsy. We at UPPR see this changing and UPPR, through its wholly owned subsidiary, is at the forefront of this change. UPPR intends to be a leader in FDA cGMP (Current Good Manufacturing Practice) capabilities in the hemp and CBD marketplace. FDA cGMP standards are US requirements that will become the expected manufacturing requirements for all CBD products in the US. UPPR will be at the forefront of this trend and back it up with our strategic partnership with Primapharma Inc. (www.primapharma.net) which we announced on January 22, 2019, to develop fully cGMP CBD oils and isolate, as well as research and clinical studies. UPPR intends to be the industry leader in FDA cGMP standards.
Some of the CBD industry’s biggest consumers aren’t even human.
Pets are the hot new cannabis customer as owners use CBD to ease pain and thunderstorm anxiety.
Last year, Americans spent $33 billion on pet food and treats.
Sales of CBD pet products quadrupled last year to $32 million from $8 million in 2017, according to the Brightfield Group. The cannabis-focused research firm estimates the market could balloon to $1.16 billion in the U.S. alone by 2022.
European CBD market, which is expected to be worth $416 million by the end of 2019, is projected to be worth $1.7 billion by 2023.
The growth of the CBD and cannabis markets have been slower than they have been in the United States in part because in the EU, CBD is largely limited to topical use and tobacco products, while its use in ingestibles (such as food additives, tinctures and capsules) is prohibited. That may change, however, following an amendment proposed by the European Food Safety Agency to allow CBD in ingestible products, which could pass at the end of the year.
Brightfield pegs the market for hemp-derived CBD products at about $591 million in 2018, growing to $22 billion by 2022
Volume has been picking up on this sleeper!
Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will present a corporate overview and business update at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14 at the Encore Hotel in Las Vegas, Nevada.
Bank of America Merrill Lynch Health Care Conference
Date: Tuesday, May 14 Time: 5:20pm Eastern Time/2:20pm Pacific Time Loca tion: Encore Hotel, Las Vegas, Nevada Webcast: http://www.veracast.com/webcasts/baml/healthcare2019/id21112470851.cfm About Foamix
Upper Street Marketing Has Acquired Key Facility
San Diego, CA, May 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Upper Street Marketing Inc. (OTC Markets: symbol UPPR, website http://upperstreetmarketing.com) and its wholly-owned subsidiary, Growing Springs Holding Corporation, are pleased to announce that it has acquired a 95,000 square foot facility in Center, Colorado for the processing of hemp and extraction of CBD.
The price paid for the building was $1,100,000.
“This facility is a center-post for UPPR and its wholly owned subsidiary Growing Springs as it cultivates over 300 acres of organic industrial hemp in Colorado and extracts cGMP (Current Good Manufacturing Practice) CBD isolates and distillates,” said Joseph Earle, Upper Street CEO.
Further to our news release of April 25, 2019, below is a corporate update.
We embarked on an ambitious plan in 2018 to become the first and likely the largest cgMP CBD producer and marketing company in the United States and a major player in the global market for what we see as the most significant new market in many years.
So what is this significant new market and what is the potential size of this market?
In a recent Fortune Magazine article, dated February 25th, 2019 they quoted a news analysis by Cowen & Co, nearly 7% of Americans are already using cannabidiol (CBD), placing the potential for the much-hyped cannabis compound at $35 Billion by 2025.
They went on to say that they “conservatively” see CBD use growing to 10% of U.S. adults or 25 million consumers by 2025.
So far, although CBD is promoted as an effective treatment for everything from arthritis to insomnia, the only clinically proven remedies are for two rare forms of childhood epilepsy.
We see this changing and UPPR, through its wholly owned subsidiary, is at the forefront of this change.
Why do we say this?
We are one of the very few “seed to consumer” hemp and CBD companies in the world.
And we are most certainly either the only or one of the very few companies who have cGMP (Current Good Manufacturing Practice) capabilities in the hemp and CBD marketplace.
What is cGMP and why is that so valuable and important?
Because cGMP regulations are enforced by the FDA (the U.S. Food and Drug Administration) and that capability to meet FDA rules and regulations for CBDs puts us at the forefront of what is already happening and what is about to come.
More and more, CBD products will have to be approved by the FDA and backed up by science when the manufacturers and sellers of CBD products make claims for their products.
As more and more science proves that CBDs are effective treatment for more and more sicknesses and maladies, very large numbers of consumers are going to demand that the products they buy be properly certified and backed up by solid science.
We at UPPR are at the forefront of that trend, and back it up with our strategic partnership with Primapharma (www.primapharma.net) which we announced on January 22, 2019, to develop fully cGMP CBD oils and isolate, as well as research and clinical studies.
In order to be a “from seed to consumer” CBD company, we grow our own hemp, extract the high quality CBD from our own hemp and with our partnership with Primapharma, we are developing cGMP products for consumers.
This is how we are unique and how we are attacking this large and rapidly growing market that is estimated to be a $16 Billion market within the next seven years.
Upper Street Marketing Inc website; http://upperstreetmarketing.com
Nice volume so far in the right direction!
Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced it will present two late-breaking posters relating to its topical product candidate FMX101, a 4% minocycline foam being developed for the treatment of moderate-to-severe acne, at the 77th Annual Meeting of the Society for Investigative Dermatology to be held May 8-11, 2019, in Chicago, Illinois. Foamix previously announced that the U.S. Food & Drug Administration (FDA) has accepted the filing of a New Drug Application for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older and the FDA has set an action date of October 20, 2019 under the Prescription Drug User Fee Act (PDUFA).
Poster Presentation Details:
Title: The Impact of FMX101 on the Physical Properties of Human Sebum: Comparison of an Oil-Based Formulation vs an Oil-in-Water Emulsion
Poster Number: LB1118
Authors: Yohan Hazot; Lenny Margulis, PhD; Shay Burban; Russell Elliott, PhD; Iain Stuart, PhD
Poster Session I; Thursday May 9, 2019; 10:45 am - 12:45 pm Central Time
Location: Late-breaking posters LB 1046 - LB 1144
Title: Assessing Bacterial Susceptibility of FMX101 4% Topical Minocycline Foam
Poster Number: LB1117
Authors: Joyce Sutcliffe, PhD; Robert McLaughlin, PhD; James Del Rosso, DO; Jonathan Weiss, MD; Hilary Baldwin, MD; Guy Webster, MD PhD; James Leyden, MD; Xilin Zhao, PhD; Andrew Read, PhD; Karl Drlica, PhD; Russell Elliott, PhD; Iain Stuart, PhD
Poster Session II; Friday, May 10, 2019; 11:15 am - 1:15 pm Central Time
Location: Late-breaking posters LB 1047 - LB 1143
Members of the Foamix R&D team will be on-site at the conference to present the research in these sessions. Research abstracts will also be published in the Journal of Investigative Dermatology this fall and will be available as handouts at the SID 2019 meeting.
About the Society for Investigative Dermatology (SID) and the SID Annual Meeting
The Mission of the Society for Investigative Dermatology (SID) is to advance and promote scientific evidence relevant to skin health and disease through education and scholarly exchange of scientific information, with the intent to foster improvement in the competence (abilities, skills and strategies) of dermatology researchers and clinicians.
The 77th Annual Meeting of the SID is a forum in which a diverse community of scientists comes to exchange information on the latest advances. The SID Annual Meeting draws a diverse group of senior researchers and clinicians, as well as hundreds of clinical trainees including dermatology residents. These healthcare professionals and basic researchers are on the frontline for recognizing systemic disease (including many types of cancer) with a skin-related association. For additional information, visit https://www.sidannualmeeting.org/.
Company’s Stockholders 2019 Annual Meeting
In addition, on April 25, 2019, the Board of Directors (the “Board”) of the Company amended and restated the Company’s bylaws (the “Bylaws”) to establish advance notice requirements for stockholder nominations for election to the Board and for other proposals to be brought by stockholders before meetings of the Company’s stockholders. With respect to the 2019 annual meeting of stockholders, which the Company intends to hold on July 10, 2019, stockholder nominations and other proposals must be received no later than the close of business on May 6, 2019 to be timely.
BioPharmX Completes 1-for-25 Reverse Stock Split
SAN JOSE, Calif., Apr. 26, 2019/PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the “Company”), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the completion of the reverse stock split previously announced on April 15, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock. The reverse stock split became effective at 4:01 pm Eastern Time on April 25, 2019.
As a result of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock at the time of the reverse stock split have been automatically combined into one issued and outstanding share of common stock. The reverse stock split affected all stockholders uniformly and will neither alter any stockholder's percentage ownership interest in the Company nor have any direct impact on the market capitalization of the Company. The number of outstanding shares of common stock has been reduced from approximately 262.0 million shares to approximately 10.5 million shares.
Upper Street Marketing Corporate Update and Mission Statement
SAN DIEGO, CA, April 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Upper Street Marketing Inc. (OTC: UPPR) and its wholly-owned subsidiary, Growing Springs Holding Corporation, are pleased to share the following corporate update and Mission Statement.
Although the passing of the Farm Bill in December 2018 has dramatically boosted the planned production and cultivation of industrial hemp in the US, the “status quo” of producers of CBD products, do largely NOT adhere to the Food and Drug Administration (FDA) standards. The FDA oversees the sales and distribution CBD products in the US.
The average hemp farmer in the US farms 37 acres of industrial hemp. The entire production of CBD isolate in 2018 was under 50,000 kilos. Based on current projections by Fortune Magazine, and others, CBD sales will hit $25 billion by 2022. The wholesale CBD demand in the US and Canada will call for a 100X of current production to as many as 3,500,000 kilos of CBD isolate by 2023. The fragmented and inefficient industrial hemp and CBD industry is largely not ready for this expansion.
Additionally, the FDA is stepping up intense scrutiny of all stages of the CBD industry and has recently sent “Cease and Desist” letters to a number of large producers and distributors. Producers and distributors that do not meet FDA standards, will risk governmental and regulatory shut-down. UPPR will meet and in fact exceed these regulatory and manufacturing standards and will lead the industry.
UPPR – Growing Springs Holdings Corporation (OTC: UPPR) offer significant advantages over determined competitors. Those advantages include, but are not limited to the following:
1. UPPR along with its pharmaceutical manufacturing partner, PrimaPharm Inc., (www.primapharm.net) apply FDA cGMP standards to all phases of industrial hemp cultivation and CBD extraction. These standards apply to genetics, certified organic soil used in cultivation, organic nutrients and other specialty chemicals applied to cultivation, cultivation procedures, harvest, processing and extraction of CBD isolate and/or distillate needed for significant sales channels. UPPR applies active pharmaceutical ingredient (API) track and trace to all phases of operations.
2. UPPR utilizes mass cultivation in excess of 360 acres for 2019and larger cultivation for 2020 and beyond in order to accumulate the bio-mass needed for mass extraction of pharmaceutical grade wholesale CBD products. UPPR intends to extract as many as 150,000 kilos of CBD Isolate annually by 2021.
3. UPPR uses proprietary hemp genetics, organic certified soil and specialty nutrients needed to meet its aggressive cGMP standards and pharmaceutical standards required by large international buyers and distributors.
4. UPPR has strategically placed key facilities in geographic areas needed to meet sales channel demands. UPPR owns and operates a 100,000 square foot CBD manufacturing and processing facility in Center, Colorado. UPPR also operates a 13,000 extraction and laboratory facility on an FDA licensed facility in San Diego, California.
5. UPPR will apply FDA cGMP standards to collaborations, joint venture partners as well as strategic acquisitions needed to expand its operations and manufacturing over the next 36 months.
UPPR is well positioned to be a large wholesale CBD producer and industry leader for 2019 and beyond.
Looking forward to it! Adding along the way!